Overview
- The FDA has authorized at-home HPV self-collection, allowing adults to collect samples outside clinics to lower barriers tied to time, discomfort, and access.
- The American Cancer Society updated its guidance in December 2025 to accept HPV self-collection, reinforcing a shift toward more sensitive primary HPV testing.
- Early data from Teal Health’s authorized home test show strong uptake among women ages 40 to 65, with nearly half overdue or never previously screened.
- Clinicians in India report more cervical cancer diagnoses in younger women, linking the shift to early HPV exposure, low vaccination coverage, and delayed screening.
- Experts underscore vaccination plus routine screening as the core strategy, noting WHO’s elimination goal and U.S. estimates of roughly 13,000 to 14,000 cases this year.